Ostatní
Návod 
PureTech Health plc
PRTC
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.4B
Obrat
0B
Zisk
0B
Aktiva
1B
Dluh
0B
ROE
-3%
ROA
-2%
PE
-32
PS
60
Cena 1R
13-20
⌀ Cena
17.50
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
28-04-2026
Poslední dividenda
Profil
PureTech Health plc, bioterapeutická společnost v klinickém stadiu, objevuje, vyvíjí a komercializuje léky pro zánětlivé, fibrotické a imunologické, nitrožilní rakoviny, lymfatické a gastrointestinální, neurologické a neuropsychologické a další nemoci ve Spojených státech. Společnost nabízí KarXT zaměřující se na muskarinové acetylcholinové receptory k léčbě schizofrenie a psychózy u Alzheimerovy choroby; regenerační biologickou platformu pro androgenetickou alopecii, stárnutí epitelu a další zdravotní stavy; imunomodulační platformu k léčbě chronických a akutních zánětlivých poruch; perorální terapie založené na definovaných konsorciích bakterií je izolována od lidského mikrobiomu; a terapie k léčbě kognitivních dysfunkcí spojených s depresí, roztroušenou sklerózou, post COVID a ICU a rakovinnými stavy. Poskytuje také hematopoetické terapie založené na kmenových buňkách pro pacienty s rakovinou krve, technologickou platformu založenou na hlasu pro detekci změn hlasu spojených se zdravotními stavy a technologickou platformu pro orální aplikaci biologických léčiv, vakcín a dalších léků. Kromě toho společnost vyvíjí LYT-100 pro léčbu lymfedému a dalších poruch lymfatického toku; LYT-200, monoklonální protilátku IgG4 proti galektinu-9; LYT-210 pro léčbu solidních nádorů; Glyf, syntetickou platformu cílené chemie lymfatických buněk; Orasomovou technologii umožňující perorální podávání makromolekulárních léčebných dávek; platformu meningeální lymfatiky pro léčbu Alzheimerových a Parkinsonových onemocnění; a platformu technologie Alivio pro záněty imunomodulace onemocnění. Společnost PureTech Health plc spolupracuje a uzavírá licenční smlouvy se společnostmi Boehringer Ingelheim International GMBH, Eli Lilly and Company, Imbrium Therapeutics L.P. a Shionogi & Co., Ltd. Společnost byla založena v roce 2015 a má sídlo v Bostonu v Massachusetts.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
80
Založení
2020-11-16
Podobné společnosti
$ 1.37
+ $ 0.04
$ 1.61
+ $ 0.03
$ 1.81
+ $ 0.05
$ 3.15
- $ 0.03
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 6.3 | 4.8 | 3.3 | 2.1 | 10.0 | 8.3 | 8.7 | 16.4 | 0.7 | 4.4 | 11.7 | 2.0 | 7.0 | 7.9 | |
| Cost of Revenues | 44.4 | 0.0 | 4.9 | 0.0 | 0.0 | 0.0 | 0.0 | -4.4 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | -38.1 | 1.3 | -1.6 | 2.1 | 10.0 | 8.3 | 8.7 | 20.7 | 0.7 | 4.4 | 11.8 | 2.0 | 7.0 | 7.9 |
| Revenue | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 1.9 | 4.0 | 0.3 | 0.1 | 0.2 | 0.1 | 3.2 | 1.6 | 3.4 | |
| Cost of Revenues | 24.9 | -38.9 | 38.9 | 19.5 | 1.9 | 21.5 | 3.1 | 26.6 | 19.1 | |
| Gross Profit | -23.0 | 43.0 | -38.6 | -19.3 | -1.7 | -21.5 | 0.1 | -25.0 | -15.7 |
| Operating Income | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 19.5 | 0.0 | 96.2 | 116.1 | 81.5 | 61.2 | 65.2 | 57.3 | 71.7 | 41.2 | 13.4 | 2.8 | 2.8 | 4.2 | |
| Selling General & Admin Expenses | 13.9 | 0.0 | 48.4 | 35.7 | 30.8 | 26.5 | 34.9 | 24.4 | 46.3 | 37.2 | 18.4 | 7.2 | 3.6 | 3.8 | |
| Depreciation & Amortization | 6.2 | 3.6 | 4.9 | -4.9 | -64.6 | -25.2 | 40.5 | 2.8 | 2.1 | 1.6 | 0.7 | 0.5 | 0.5 | 0.5 | |
| Total Operating Expenses | 179.2 | 140.4 | 146.9 | 199.9 | 160.3 | 127.9 | 144.1 | 120.4 | 116.1 | 78.4 | 55.4 | 19.5 | 10.1 | 14.0 | |
| Operating Income | -217.2 | -136.1 | -146.2 | -197.8 | -150.3 | -119.5 | -135.4 | -104.0 | -115.4 | -73.9 | -43.6 | -17.4 | -3.7 | -9.4 |
| Operating Income | TTM | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 19.5 | 42.7 | 21.5 | 53.1 | 26.6 | 0.0 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 13.9 | 25.1 | 13.6 | 23.1 | 13.1 | 19.1 | ||
| Depreciation & Amortization | 1.7 | 1.8 | 1.8 | 0.9 | 1.9 | 1.0 | 3.1 | 1.5 | 1.6 | ||
| Total Operating Expenses | 24.9 | 112.7 | 27.8 | 13.9 | 67.8 | 10.4 | 76.3 | 16.8 | 19.1 | ||
| Operating Income | -47.9 | -69.7 | -66.4 | -33.2 | -69.5 | -35.0 | -76.2 | -38.1 | -26.4 |
| Net Income | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 29.8 | 22.7 | 16.0 | 5.8 | 0.2 | 1.2 | 4.4 | 3.4 | 1.8 | 1.3 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Interest Expense | 11.0 | 10.0 | 13.5 | 4.0 | 4.7 | 2.9 | 2.6 | 0.4 | 0.6 | 0.8 | 0.8 | 2.6 | 0.4 | 0.6 | |
| Other Expense | 169.6 | 159.9 | 110.1 | 105.0 | 91.3 | 138.5 | 613.9 | 35.6 | 44.7 | -9.3 | -12.7 | -58.8 | -1.6 | -1.4 | |
| IBT | -47.6 | 23.8 | -36.1 | -92.8 | -59.0 | 19.0 | 478.5 | -68.4 | -70.7 | -83.2 | -56.3 | -76.2 | -5.3 | -10.8 | |
| Income Tax Expense | 0.0 | -4.0 | 30.5 | -55.7 | 3.8 | 14.4 | 112.4 | 2.2 | 0.0 | -1.6 | 1.9 | -0.3 | 0.3 | 0.5 | |
| Net Income | -12.0 | 53.5 | -65.7 | -37.1 | -62.7 | 4.6 | 421.1 | -43.7 | 30.9 | -48.8 | -39.4 | -41.6 | -4.3 | -11.1 |
| Net Income | TTM | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 7.1 | 10.9 | 11.7 | 0.0 | 8.2 | 0.1 | 7.7 | 1.4 | 0.0 | ||
| Interest Expense | 1.0 | -1.3 | 11.4 | 0.0 | 8.4 | 0.0 | 5.0 | 0.0 | -0.6 | ||
| Other Expense | 4.1 | 148.5 | 11.4 | 5.7 | 48.0 | 23.8 | 29.7 | 31.2 | 113.6 | ||
| IBT | -43.9 | 78.8 | -55.0 | -27.5 | -21.5 | -11.2 | -8.4 | -6.9 | 87.2 | ||
| Income Tax Expense | 0.9 | 2.1 | -6.1 | 3.1 | 18.6 | 9.4 | 11.8 | 5.9 | 25.4 | ||
| Net Income | -44.6 | 95.3 | -41.8 | -20.9 | -40.4 | -20.3 | -25.0 | -12.5 | 62.0 |
| Per Share Data | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $-0.08 | $0.00 | $-2.38 | $-1.30 | $-2.19 | $0.16 | $14.90 | $-1.59 | $1.30 | $-2.13 | $-2.13 | $-1.83 | $-0.19 | $-0.49 | |
| EPS Diluted | $-0.08 | $0.00 | $-0.24 | $-1.30 | $-2.19 | $0.16 | $14.40 | $-1.59 | $1.30 | $-2.13 | $-2.13 | $-1.83 | $-0.19 | $-0.49 | |
| Shares Outstanding | 23.5 | 27.0 | 27.6 | 28.5 | 28.7 | 28.6 | 28.3 | 27.4 | 23.6 | 23.0 | 18.5 | 22.7 | 22.7 | 22.7 | |
| Diluted Shares Outstanding | 24.0 | 27.0 | 276.3 | 28.5 | 28.7 | 29.3 | 29.2 | 27.4 | 23.9 | 23.0 | 18.5 | 22.7 | 22.7 | 22.7 |
| Per Share Data | TTM | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-0.08 | $-0.07 | $-0.07 | $-0.04 | $-0.04 | $2.11 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-0.08 | $-0.08 | $-0.08 | $-0.05 | $-0.05 | $2.11 | ||
| Shares Outstanding | 23.5 | 27.0 | 27.0 | 269.7 | 270.5 | 270.5 | 277.8 | 277.8 | 29.4 | ||
| Diluted Shares Outstanding | 24.0 | 27.0 | 27.0 | 269.7 | 274.4 | 274.4 | 278.3 | 278.3 | 29.4 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 310.1 | 280.6 | 191.1 | 149.9 | 465.7 | 403.9 | 132.4 | 117.1 | 72.6 | 63.0 | 134.8 | 219.0 | 7.2 | 10.9 | |
| Short Term Investments | 0.0 | 86.7 | 136.1 | 200.2 | 0.0 | 0.0 | 30.1 | 133.8 | 117.0 | 219.4 | 179.8 | 1.2 | 1.8 | 1.2 | |
| Total Cash & ST Investments | 310.1 | 367.3 | 327.1 | 350.1 | 465.7 | 403.9 | 162.4 | 250.9 | 189.7 | 282.4 | 314.5 | 220.1 | 9.0 | 12.0 | |
| Accounts Receivable | 2.1 | 12.9 | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 196.6 | 6.0 | 17.7 | 0.0 | 0.0 | 0.0 | 0.0 | 8.9 | 9.4 | 7.6 | 3.7 | 3.6 | 3.1 | 1.5 | |
| Total Current Assets | 508.8 | 386.3 | 347.2 | 386.2 | 501.8 | 414.3 | 168.8 | 259.8 | 198.1 | 288.2 | 318.2 | 223.7 | 12.1 | 13.5 |
| Current Assets | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 260.6 | 280.6 | 308.5 | 308.5 | 192.7 | 191.1 | 350.5 | 350.5 | 149.9 | 365.9 | |
| Short Term Investments | 59.3 | 86.7 | 191.9 | 191.9 | 136.1 | 136.1 | 1.6 | 0.0 | 200.2 | 2.1 | |
| Total Cash & ST Investments | 321.6 | 367.3 | 500.4 | 500.4 | 328.8 | 327.1 | 352.1 | 350.5 | 350.1 | 368.0 | |
| Accounts Receivable | 13.9 | 12.9 | 2.1 | 2.1 | 2.4 | 2.4 | 2.3 | 2.3 | 0.0 | 0.0 | |
| Inventory | 0.0 | 0.0 | 0.0 | 4.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 9.0 | 6.0 | 6.3 | 6.3 | 17.7 | 17.7 | 5.7 | 7.3 | 0.0 | 0.0 | |
| Total Current Assets | 344.4 | 386.3 | 508.8 | 508.8 | 347.2 | 347.2 | 360.1 | 360.1 | 386.2 | 381.8 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 17.3 | 15.1 | 19.4 | 37.2 | 43.9 | 42.9 | 43.8 | 8.3 | 6.9 | 6.9 | 4.5 | 1.2 | 1.2 | 1.1 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.6 | 0.9 | 0.8 | 1.0 | 0.9 | 0.6 | 3.1 | 3.3 | 3.5 | 3.9 | 3.0 | 3.2 | 3.3 | |
| Long-Term Investments | 45.2 | 200.2 | 325.6 | 60.8 | 0.0 | 0.0 | 695.5 | 35.9 | 14.3 | -219.3 | -179.7 | -1.1 | -1.6 | 0.0 | |
| Other Long-Term Assets | 0.9 | 0.5 | 0.9 | 278.4 | 399.3 | 531.9 | 32.3 | 134.2 | 117.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | |
| Total Long-Term Assets | 71.1 | 216.4 | 346.8 | 316.5 | 444.2 | 575.6 | 772.3 | 182.0 | 141.7 | 10.6 | 8.6 | 4.3 | 4.6 | 5.6 | |
| Total Assets | 580.0 | 602.6 | 694.0 | 702.6 | 946.0 | 990.0 | 941.2 | 441.8 | 339.8 | 298.7 | 326.8 | 228.0 | 16.8 | 19.2 |
| Long-Term Assets | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 13.3 | 15.1 | 17.3 | 17.3 | 19.4 | 19.4 | 21.5 | 21.5 | 37.2 | 41.4 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.6 | 0.6 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 | 1.0 | |
| Long-Term Investments | 194.5 | 200.2 | 45.2 | 45.2 | 325.6 | 325.6 | 283.6 | 309.9 | 60.8 | 395.8 | |
| Other Long-Term Assets | 0.5 | 0.5 | 0.9 | 7.7 | 0.9 | 0.9 | 1.0 | 1.1 | 278.4 | 3.2 | |
| Total Long-Term Assets | 208.9 | 216.4 | 71.1 | 71.1 | 346.8 | 346.8 | 333.5 | 333.5 | 316.5 | 441.3 | |
| Total Assets | 553.2 | 602.6 | 580.0 | 580.0 | 694.0 | 694.0 | 693.6 | 693.6 | 702.6 | 823.2 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 8.1 | 5.5 | 14.6 | 26.5 | 11.3 | 8.9 | 11.1 | 4.6 | 16.4 | 11.1 | 2.4 | 4.7 | 0.9 | 1.2 | |
| Short-Term Debt | 77.5 | 7.7 | 7.1 | 12.5 | 8.7 | 29.7 | 4.4 | 12.0 | 7.5 | 7.0 | 5.0 | 6.9 | 4.3 | 1.5 | |
| Other Current Liabilities | 26.6 | 28.1 | 29.6 | 57.9 | 174.7 | 119.7 | 101.5 | 218.3 | 121.0 | 97.6 | 66.1 | 11.8 | 10.1 | 7.9 | |
| Current Liabilities | 138.3 | 41.4 | 51.4 | 96.9 | 226.1 | 180.9 | 139.2 | 265.8 | 273.9 | 204.1 | 160.5 | 93.7 | 22.8 | 21.4 |
| Current Liabilities | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.7 | 5.5 | 8.1 | 8.1 | 14.6 | 14.6 | 8.7 | 8.7 | 26.5 | 15.1 | |
| Short-Term Debt | 8.0 | 7.7 | 10.9 | 10.9 | 7.1 | 7.1 | 5.6 | 5.6 | 12.5 | 9.5 | |
| Other Current Liabilities | 27.9 | 28.1 | 67.1 | 119.3 | 29.6 | 29.6 | 22.8 | 35.0 | 57.9 | 125.6 | |
| Current Liabilities | 40.6 | 41.4 | 138.3 | 138.3 | 51.4 | 51.4 | 49.3 | 49.3 | 96.9 | 150.3 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 0.0 | 14.7 | 18.3 | 34.4 | 43.3 | 46.9 | 34.9 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Capital Leases | 16.4 | 18.3 | 21.6 | 29.1 | 33.0 | 35.3 | 37.8 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 52.5 | 19.6 | 89.8 | 108.6 | 115.4 | 6.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 273.7 | 194.7 | 235.7 | 155.1 | 361.9 | 336.5 | 290.8 | 274.8 | 275.8 | 206.3 | 162.7 | 94.3 | 24.8 | 22.5 |
| Long-Term Liabilities | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 12.9 | 14.7 | 16.4 | 133.9 | 18.3 | 128.4 | 20.0 | 123.7 | 34.4 | 38.6 | |
| Capital Leases | 16.4 | 18.3 | 20.0 | 20.0 | 18.3 | 21.6 | 23.2 | 23.2 | 29.1 | 31.3 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 52.5 | 0.0 | 9.1 | 0.0 | 19.6 | 57.3 | |
| Total Liabilities | 184.2 | 194.7 | 273.7 | 273.7 | 125.6 | 235.7 | 184.7 | 184.7 | 155.1 | 247.1 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 4.9 | 4.9 | 5.5 | 5.5 | 5.4 | 5.4 | 5.4 | 5.4 | 4.7 | 4.6 | 4.5 | 159.4 | 1.3 | 1.3 | |
| Retained Earnings | 76.0 | 32.5 | 83.8 | 149.5 | 199.9 | 260.4 | 254.4 | -167.7 | -127.9 | -160.3 | -111.4 | -70.4 | -35.1 | -30.9 | |
| Comprehensive Income | -8.4 | 134.0 | 129.1 | 0.0 | 0.0 | 0.0 | 0.0 | -6.1 | -3.9 | -2.2 | -1.1 | -0.6 | -0.5 | -0.3 | |
| Total Common Equity | 315.9 | 414.7 | 464.1 | 542.2 | 593.5 | 669.7 | 668.0 | 275.5 | 214.3 | 177.7 | 226.1 | 179.0 | -0.9 | 3.1 |
| Total Common Equity | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 4.9 | 4.9 | 4.9 | 4.9 | 5.5 | 5.5 | 5.5 | 5.5 | 5.5 | 5.4 | |
| Retained Earnings | -12.1 | 32.5 | -62.5 | -62.5 | 222.3 | 83.8 | 124.5 | 124.5 | 149.5 | 171.5 | |
| Comprehensive Income | 137.7 | 134.0 | 130.1 | 130.1 | 0.2 | 129.1 | -12.0 | 126.5 | 0.0 | 0.0 | |
| Total Common Equity | 376.0 | 414.7 | 315.9 | 315.9 | 464.1 | 464.1 | 513.7 | 513.7 | 542.2 | 581.8 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 93.9 | 22.4 | 25.3 | 46.9 | 52.0 | 76.6 | 39.3 | 12.4 | 7.5 | 7.0 | 5.0 | 6.9 | 4.3 | 1.5 | |
| Book Value | 306.2 | 407.9 | 458.2 | 547.6 | 584.1 | 653.5 | 650.4 | 167.0 | 64.0 | 92.4 | 164.1 | 133.7 | -8.0 | -3.4 |
| Other | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | -7.0 | -6.8 | -9.7 | -9.7 | -5.8 | -5.8 | -4.8 | -4.8 | 5.4 | -5.7 | |
| Book Value | 376.0 | 414.7 | 315.9 | 315.9 | 464.1 | 464.1 | 513.7 | 513.7 | 542.2 | 581.8 |
| Cash Flow From Operating Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -127.5 | 27.8 | -65.7 | -37.1 | -62.7 | 4.6 | 366.1 | -70.7 | -70.7 | -81.6 | -58.2 | -75.9 | -5.2 | -12.2 | |
| Depreciation & Amortization | 7.7 | 3.6 | 4.9 | 8.9 | 7.3 | 6.6 | 6.7 | 2.8 | 2.1 | 1.6 | 0.7 | 0.5 | 0.5 | 0.5 | |
| Stock-Based Compensation | 3.8 | 22.9 | 4.4 | 14.7 | 14.0 | 10.7 | 14.5 | 12.6 | 11.8 | 10.2 | 11.1 | 2.8 | 0.3 | 0.4 | |
| Change Working Capital | 1.6 | -10.2 | 17.5 | 15.9 | 0.9 | -8.5 | 15.0 | 10.0 | 3.0 | 1.9 | 4.8 | 2.9 | -6.0 | 5.1 | |
| Change In Accounts Receivable | 10.2 | 0.6 | 9.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Change In Accounts Payable | -13.1 | -9.7 | 3.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | -104.8 | -178.3 | -67.1 | -181.2 | -5.1 | 6.1 | 46.2 | -8.1 | 81.9 | 10.7 | 13.4 | 59.0 | 0.2 | 1.5 | |
| Cash from Operations | -205.5 | 0.0 | -105.9 | -178.8 | -158.3 | -131.8 | -98.2 | -72.8 | -88.7 | -58.0 | -28.6 | -10.5 | -8.8 | -1.5 |
| Cash Flow From Operating Activities | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -44.6 | 69.6 | -41.8 | -20.9 | -40.4 | -20.3 | -25.0 | -12.5 | 62.0 | |
| Depreciation & Amortization | 1.7 | 1.8 | 1.8 | 0.9 | 1.9 | 0.9 | 3.1 | 1.5 | 1.6 | |
| Stock-Based Compensation | 4.7 | 18.2 | 4.6 | 2.3 | 1.6 | 1.6 | 0.6 | 0.6 | 0.0 | |
| Change Working Capital | -0.3 | -10.2 | -0.1 | 0.0 | 15.3 | 1.1 | 2.1 | 5.8 | 103.9 | |
| Change In Accounts Receivable | -0.9 | 0.0 | 0.6 | 0.2 | 0.4 | 0.3 | 9.2 | 4.6 | 0.0 | |
| Change In Accounts Payable | 0.0 | 0.0 | 0.0 | 0.0 | 13.1 | 0.0 | -9.3 | 0.0 | 0.0 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | -7.9 | -132.4 | -44.6 | -22.3 | -59.1 | -3.7 | -39.1 | -28.1 | -167.4 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | -40.0 | -39.9 | -20.4 | -65.1 | -32.6 | 0.0 |
| Cash Flow From Investing Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.2 | 0.0 | -0.2 | -2.2 | -5.7 | -5.4 | -12.5 | -4.5 | -2.2 | -3.7 | -4.6 | -0.4 | -0.6 | -1.5 | |
| Acquisitions | -12.6 | -106.0 | -13.8 | -20.4 | 0.3 | -10.0 | -16.0 | -13.4 | -16.3 | 0.0 | 1.2 | 0.1 | 0.1 | 0.6 | |
| Investments | -407.2 | -309.6 | -195.7 | -268.7 | -0.5 | -1.2 | -91.2 | -170.0 | -147.2 | -312.8 | -385.4 | -2.2 | -3.5 | -2.5 | |
| Sales of Investment | 725.0 | 656.2 | 277.9 | 183.7 | 218.1 | 380.7 | 183.3 | 148.1 | 249.4 | 273.3 | 205.8 | 3.4 | 3.1 | 3.8 | |
| Other Investing Activities | -17.9 | 0.0 | 0.9 | 0.4 | -14.9 | 0.4 | 0.2 | 0.1 | 0.0 | 0.0 | -1.2 | -0.1 | 0.1 | -0.6 | |
| Cash from Investing | 252.5 | 0.0 | 69.0 | -107.2 | 197.4 | 364.5 | 63.7 | -39.6 | 83.7 | -43.2 | -184.2 | 0.7 | -0.9 | -0.2 |
| Cash Flow From Investing Activities | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | -0.1 | 0.0 | -1.0 | |
| Acquisitions | 0.0 | -90.6 | 0.2 | 0.0 | 0.4 | 0.0 | -13.2 | 0.0 | 0.0 | |
| Investments | 0.0 | -107.7 | -213.0 | 0.0 | -178.8 | 0.0 | -15.4 | 0.0 | -6.3 | |
| Sales of Investment | 0.0 | 200.3 | 449.4 | 0.0 | 73.2 | 0.0 | 202.5 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 118.3 | -52.4 | -52.4 | 87.0 | 87.0 | 7.4 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 118.3 | -105.4 | -52.4 | 173.9 | 86.9 | 0.1 |
| Cash Flow From Financing Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -200.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | -0.2 | -0.2 | 0.0 | -0.4 | 0.0 | 0.0 | -3.9 | |
| Debt Issued | 193.3 | -3.0 | -21.5 | -5.2 | -24.6 | 37.3 | 27.1 | 5.1 | 0.7 | 2.0 | -1.6 | 2.7 | 2.8 | 5.3 | |
| Issuance of Common Stock | 70.1 | 0.0 | 1.2 | 0.3 | -12.9 | -11.8 | 50.3 | 152.0 | 12.4 | 27.3 | 235.7 | 55.8 | 0.0 | 0.7 | |
| Repurchase of Common Stock | -132.1 | -107.6 | -19.7 | -26.5 | 0.0 | 0.0 | 1.2 | 0.0 | -0.1 | 0.0 | 0.0 | 9.1 | 0.0 | 1.3 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -1.1 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | |
| Other Financing Activities | 98.5 | 0.0 | 97.8 | -3.7 | 35.6 | 50.6 | -1.3 | 6.1 | 2.6 | 2.2 | 50.6 | -0.1 | 6.0 | 3.3 | |
| Cash from Financing | 31.5 | 0.0 | 78.1 | -29.8 | 22.7 | 38.9 | 49.9 | 156.9 | 14.7 | 29.5 | 285.9 | 64.7 | 5.9 | 1.3 |
| Cash Flow From Financing Activities | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.0 | 100.0 | 0.0 | -0.6 | |
| Debt Issued | 20.9 | 22.4 | -97.5 | 99.2 | -6.6 | 106.5 | -0.5 | 79.2 | 39.1 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -2.1 | -1.1 | -106.4 | -53.2 | -12.2 | -6.2 | -7.3 | -3.6 | -6.3 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 33.7 | 97.7 | -0.7 | -47.7 | 49.6 | 5.8 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | -19.6 | -14.4 | -6.9 | 91.9 | 45.9 | -1.1 |
| Cash position | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 78.4 | 89.6 | 41.2 | -315.8 | 61.8 | 271.5 | 15.3 | 44.4 | 9.7 | -71.8 | 72.8 | 54.8 | -3.7 | -0.4 | |
| Closing Cash Balance | 310.1 | 280.6 | 191.1 | 149.9 | 465.7 | 403.9 | 132.4 | 117.1 | 72.6 | 63.0 | 134.8 | 62.0 | 7.2 | 10.9 |
| Cash position | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -20.0 | -27.8 | 117.4 | 58.7 | -159.4 | -79.7 | 200.1 | 100.3 | -1.0 | |
| Closing Cash Balance | 260.6 | 280.6 | 310.1 | 58.7 | 192.7 | -79.7 | 352.1 | 100.3 | -1.0 |
| Free Cash Flow | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -205.7 | -134.4 | -106.2 | -181.0 | -163.9 | -137.3 | -110.7 | -77.3 | -90.9 | -61.7 | -33.2 | -11.0 | -9.4 | -2.9 | |
| Real Free Cash Flow | -209.5 | -157.2 | -110.6 | -195.7 | -177.9 | -148.0 | -125.2 | -89.9 | -102.7 | -71.9 | -44.3 | -13.8 | -9.7 | -3.3 |
| Free Cash Flow | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -45.9 | -54.4 | -80.0 | -40.0 | -40.1 | -20.4 | -65.2 | -32.6 | -1.0 | |
| Real Free Cash Flow | -50.7 | -72.6 | -84.7 | -42.3 | -41.7 | -22.0 | -65.8 | -33.2 | -1.0 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -31.8 | -4.5 | -1.4 |
| P/S | 60.4 | 1752.2 | 9.4 |
| P/B | 1 | 4.1 | 5.2 |
| P/FCF | -1.5 | -600.1 | -1.5 |
| Market cap | $0.4 | $1.0 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 3.8 % | 7.9 % | 0 % |
| Debt to Income | -174.6 % | -30.3 % | 0 % |
| Debt to Free cash flow | -8.4 % | -472 % | 0 % |
| Interest expense percentage | -5.1 % | -4.3 % | 44.7 % |
| Current ratio | 8.5 | 5.7 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -3.2 % | -10.1 % | 0 % |
| ROA | -2.2 % | -5.7 % | 0 % |
| CapEx to Revenue | 0.2 % | 14.9 % | 0 % |
| RaD to Revenue | 308.5 % | 4336.6 % | 0 % |
| ROEM | 31.6 | 0.7 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | -603.1 % | -2819.6 % | 68.7 % |
| Operating margin | -3442.6 % | -7890.7 % | 35.5 % |
| Net margin | -189.9 % | -3531.2 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 1.1 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 24.0 mil | 27.1 mil |
| Employee count | 200.0 tis | 200.0 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
